Merck & Co. shares were climbing 3.1% in afternoon trading after the pharmaceutical giant announced a $10 billion deal to acquire respiratory-disease specialist Verona Pharma PLC. The deal adds Verona ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Verona Pharma's stock soars into record territory after buyout deal with Merck Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of ...

The enormous deal comes as the Raleigh company's market cap has ballooned to several billion dollars. Destination Triangle: ...

The global dysmenorrhea treatment market, valued at approximately USD 5,937.8 million in 2022, is projected to reach USD 6,324.5 million in 2023 and USD 13,106.5 million by 2032, exhibiting a CAGR of ...

It is best to invest regularly and consistently in good, solid dividend-paying stocks with reasonable or attractive ...